SEBI exonerates Piramal Pharma of listing and disclosure violations
SEBI’s proceedings against PPL transpired in two rounds - in the first round, an Adjudicating Officer closed the investigation, however SEBI decided to review the same.
The Securities and Exchange Board of India (SEBI) on November 8 cleared Piramal Pharma Limited (PPL) of allegations concerning violations of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations.